To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
A phase 3 trial of Furmonertinib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., now recruiting.
Overview
To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy is a phase 3 interventional study registered as NCT04853342 by Allist Pharmaceuticals, Inc., with 318 participants planned, started 2021-06-07 and due to reach its primary completion in 2026-12. Interventions recorded: Drug: Furmonertinib 80 mg and Furmonertinib 80 mg placebo.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases
Shares Shanghai Allist Pharmaceuticals, Furmonertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TrialIN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC
Shares Furmonertinib, Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.
Shares Shanghai Allist Pharmaceuticals and the tag pipeline.
- TreatmentSitneprotafib
Shares Shanghai Allist Pharmaceuticals, Non-small-cell lung cancer and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.